Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/24047060/ below:

Long-term mortality after screening for colorectal cancer

Randomized Controlled Trial

Affiliations

• ¹ Division of Gastroenterology, Minneapolis Veterans Affairs Health Care System, Minneapolis, USA.

• PMID: 24047060
• DOI: 10.1056/NEJMoa1300720

Item in Clipboard

Randomized Controlled Trial

Aasma Shaukat et al. N Engl J Med. 2013.

• ¹ Division of Gastroenterology, Minneapolis Veterans Affairs Health Care System, Minneapolis, USA.

• PMID: 24047060
• DOI: 10.1056/NEJMoa1300720

Item in Clipboard

Background: In randomized trials, fecal occult-blood testing reduces mortality from colorectal cancer. However, the duration of the benefit is unknown, as are the effects specific to age and sex.

Methods: In the Minnesota Colon Cancer Control Study, 46,551 participants, 50 to 80 years of age, were randomly assigned to usual care (control) or to annual or biennial screening with fecal occult-blood testing. Screening was performed from 1976 through 1982 and from 1986 through 1992. We used the National Death Index to obtain updated information on the vital status of participants and to determine causes of death through 2008.

Results: Through 30 years of follow-up, 33,020 participants (70.9%) died. A total of 732 deaths were attributed to colorectal cancer: 200 of the 11,072 deaths (1.8%) in the annual-screening group, 237 of the 11,004 deaths (2.2%) in the biennial-screening group, and 295 of the 10,944 deaths (2.7%) in the control group. Screening reduced colorectal-cancer mortality (relative risk with annual screening, 0.68; 95% confidence interval [CI], 0.56 to 0.82; relative risk with biennial screening, 0.78; 95% CI, 0.65 to 0.93) through 30 years of follow-up. No reduction was observed in all-cause mortality (relative risk with annual screening, 1.00; 95% CI, 0.99 to 1.01; relative risk with biennial screening, 0.99; 95% CI, 0.98 to 1.01). The reduction in colorectal-cancer mortality was larger for men than for women in the biennial-screening group (P=0.04 for interaction).

Conclusions: The effect of screening with fecal occult-blood testing on colorectal-cancer mortality persists after 30 years but does not influence all-cause mortality. The sustained reduction in colorectal-cancer mortality supports the effect of polypectomy. (Funded by the Veterans Affairs Merit Review Award Program and others.).

PubMed Disclaimer

• Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.

  Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Mandel JS, et al. N Engl J Med. 1993 May 13;328(19):1365-71. doi: 10.1056/NEJM199305133281901. N Engl J Med. 1993. PMID: 8474513 Clinical Trial.

• Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.

  Mandel JS, Church TR, Ederer F, Bond JH. Mandel JS, et al. J Natl Cancer Inst. 1999 Mar 3;91(5):434-7. doi: 10.1093/jnci/91.5.434. J Natl Cancer Inst. 1999. PMID: 10070942

• Fecal occult blood testing and the incidence of colorectal cancer.

  Singer RB. Singer RB. J Insur Med. 2002;34(2):89-91. J Insur Med. 2002. PMID: 15305783 Clinical Trial.

• Screening for colorectal cancer.

  Mandel JS. Mandel JS. Curr Opin Gen Surg. 1994:79-84. Curr Opin Gen Surg. 1994. PMID: 7584018 Review.

• [Colorectal cancer screening: where are we and where are we going?].

  Fantin A, Chiarioni G. Fantin A, et al. Recenti Prog Med. 2013 Feb;104(2):45-8. doi: 10.1701/1241.13702. Recenti Prog Med. 2013. PMID: 23535955 Review. Italian.

• Doubly blind: a systematic review of gender in randomised controlled trials.

  Phillips SP, Hamberg K. Phillips SP, et al. Glob Health Action. 2016 Apr 15;9:29597. doi: 10.3402/gha.v9.29597. eCollection 2016. Glob Health Action. 2016. PMID: 27087576 Free PMC article. Review.

• The Effects of Differing Invitation Models on the Uptake of Immunological Fecal Occult Blood Testing.

  Gruner LF, Hoffmeister M, Ludwig L, Meny S, Brenner H. Gruner LF, et al. Dtsch Arztebl Int. 2020 Jun 19;117(25):423-430. doi: 10.3238/arztebl.2020.0423. Dtsch Arztebl Int. 2020. PMID: 32885780 Free PMC article. Clinical Trial.

• Use and abuse of fecal occult blood tests: a community hospital experience.

  Soin S, Akanbi O, Ahmed A, Kim Y, Pandit S, Wroblewski I, Saleem N. Soin S, et al. BMC Gastroenterol. 2019 Sep 3;19(1):161. doi: 10.1186/s12876-019-1079-9. BMC Gastroenterol. 2019. PMID: 31481027 Free PMC article.

• Colonoscopy in Patients Aged 85 Years or Older: An Observational Study.

  Isohata N, Shimojima R, Utano K, Nemoto D, Endo S, Kato H, Takayanagi D, Aizawa M, Nemoto T, Kawarai Lefor A, Togashi K. Isohata N, et al. J Anus Rectum Colon. 2018 Oct 29;2(4):155-161. doi: 10.23922/jarc.2018-014. eCollection 2018. J Anus Rectum Colon. 2018. PMID: 31559358 Free PMC article.

• Premature Fecal Immunochemical Testing in British Columbia Canada: a Retrospective Review of Physician and Screening Participant Characteristics.

  Sanders D, Bakos B, Gentile L, Telford JJ. Sanders D, et al. J Gen Intern Med. 2020 Feb;35(2):444-448. doi: 10.1007/s11606-019-05399-4. Epub 2019 Dec 12. J Gen Intern Med. 2020. PMID: 31832926 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3